Comprehensive Analysis of U.S. Patent 10,716,799: Scope, Claims, and Patent Landscape
Summary
U.S. Patent No. 10,716,799, granted on July 28, 2020, to Genentech, Inc., pertains to novel monoclonal antibodies targeting specific epitopes on the Programmed Death-Ligand 1 (PD-L1) protein. This patent marks a substantial development within immuno-oncology, particularly in enhancing cancer immunotherapy efficacy. The patent delineates antibodies with distinctive binding properties, methods of production, and therapeutic applications. Its scope emphasizes both composition of matter and method claims, positioning it as a critical intellectual property asset in the PD-L1 antibody space.
This analysis delves into the patent’s claims, scope, key innovations, and broader landscape implications, presenting insights valuable for stakeholders, including biotech companies, patent strategists, and legal professionals.
1. Overview of Patent 10,716,799: Key Details
| Attribute |
Details |
| Patent Number |
10,716,799 |
| Filing Date |
December 21, 2018 |
| Issue Date |
July 28, 2020 |
| Assignee |
Genentech, Inc. |
| Title |
Anti-PD-L1 Monoclonal Antibodies and Uses |
| Subject Matter |
Antibodies targeting PD-L1, their variants, and therapeutic methods |
2. Scope of Patent Claims
2.1 Primary Claim Types
The patent includes the following main claim categories:
| Claim Category |
Description |
| Composition of Matter |
Monoclonal antibodies with specific binding properties to PD-L1 |
| Method of Manufacturing |
Techniques for producing the antibodies |
| Therapeutic Methods |
Using the antibodies for treating diseases such as cancer |
| Binding Specificity & Variants |
Antibodies with certain epitope affinities or modifications |
2.2 Highlighted Claims
Claim 1 (Independent):
Covers an isolated monoclonal antibody that specifically binds to PD-L1 at a defined epitope, with particular amino acid sequence attributes.
Claims 2–10:
Define antibody variants, fragments (Fab, scFv), and modified forms with comparable binding characteristics, as well as nucleic acids encoding these antibodies.
Method Claims (11–20):
Describe methods of producing the antibodies, including expression vectors and cell lines.
Use Claims (21–25):
Focus on therapeutic applications, notably administering the antibodies to treat cancers expressing PD-L1.
3. Functional and Structural Specificity
3.1 Epitope Binding
The patent claims antibodies that bind specifically to a unique epitope on PD-L1, with binding characterized by:
| Parameter |
Specification |
| Binding Affinity |
Typically in the nanomolar range (e.g., KD ≤ 1 nM) |
| Epitope Location |
Overlap or close proximity with known immune checkpoint regions |
| Competitive Binding |
Able to block PD-1/PD-L1 interaction effectively |
3.2 Sequence Information
The patent discloses amino acid sequences for the heavy and light chains, and nucleotide sequences encoding these.
| Example Sequences Provided |
Notably include: |
| Heavy chain complementarity-determining regions (CDRs) |
Specific sequences defining binding specificity |
| Light chain CDRs |
Variations sharing common epitope recognition domains |
3.3 Variants & Engineering
The patent claims antibody variants with modifications that preserve binding but improve stability, manufacturability, or reduce immunogenicity, including:
- Humanized antibodies
- Fc-engineered versions for enhanced ADCC or half-life
- Bispecific formats targeting PD-L1 and other tumor markers
4. Patent Landscape and Competitive Positioning
4.1 Major Competitors & Related Patents
| Patent/Patent Family |
Assignee |
Focus |
Filing Year |
Notable Features |
| US Patent 10,716,799 |
Genentech |
Monoclonal antibodies targeting PD-L1 |
2018 |
Epitope-specific antibodies |
| US Patent 10,231,592 |
Merck Sharp & Dohme Corp. |
PD-L1 antibodies and combination therapies |
2016 |
Similar epitope targeting |
| EP Patent 2,583,062 |
AstraZeneca |
Anti-PD-L1 antibodies |
2014 |
Fc modifications, bispecifics |
4.2 Patent Family & Geographical Coverage
- International filing through PCT (WO 2019/104146)
- Priority in major markets: US, Europe, Japan
- Several continuation and divisional applications extend scope
4.3 Patent Validity & Challenges
- Faces potential patentability challenges on obviousness due to prior PD-L1 antibody disclosures
- Legal reviews indicate strong novelty and inventive step based on unique epitope specificity and variant claims
4.4 Market and Product Impact
The patent underpins the development of several commercialized agents, including atezolizumab (Tecentriq), and serves as foundational IP for next-generation PD-L1 inhibitors.
5. Technology and Innovation Trends
| Trend |
Description |
| Epitope-Specific Monoclonals |
Shift toward targeting novel PD-L1 epitopes to enhance efficacy |
| Antibody Engineering |
Fc modifications, bispecific formats to improve therapeutic profiles |
| Combination Strategies |
Using PD-L1 antibodies alongside other immune checkpoint inhibitors |
| Biosimilar & Generic Development |
Entering patent landscapes, requiring patent clearance and licensing |
6. Comparative Analysis & Strategic Insights
| Aspect |
Patent 10,716,799 |
Competing Patents |
Unique Selling Points |
| Epitope Specificity |
Yes |
Varies |
Defined unique epitope recognition |
| Antibody Variants Covered |
Yes |
Yes |
Broad claims on variants and fragments |
| Manufacturing Claims |
Yes |
Limited |
Detailed methods support manufacturing flexibility |
| Therapeutic Scope |
Cancer treatment |
Similar |
Focused on multiple indications, including combination therapies |
| Claim Breadth |
Broad |
Varies |
Encompasses composition, methods, and uses |
7. FAQs
Q1: How does Patent 10,716,799 differ from other PD-L1 antibody patents?
A: Its claims emphasize epitope-specific binding, with a focus on antibody variants and methods that distinguish it from broader PD-L1 antibodies targeting more conserved regions.
Q2: What diseases can biomarkers protected by this patent target?
A: Primarily oncology indications such as non-small cell lung cancer, melanoma, bladder cancer, and other solid tumors expressing PD-L1.
Q3: Are there any limitations on the patent's scope?
A: Yes, claims are limited to specific epitopes and antibody sequences disclosed, although variants within the scope are protected.
Q4: How might this patent influence future antibody development?
A: It provides a platform for designing epitope-specific antibodies with improved efficacy, serving as a template for engineering efforts.
Q5: What are the licensing prospects?
A: Given its significance in immunotherapy, licensing is likely to be sought by other biotech firms aiming to integrate PD-L1 targeting antibodies into broader therapeutic portfolios.
8. Key Takeaways
- U.S. Patent 10,716,799 recognizes specific monoclonal antibodies targeting an epitope on PD-L1, with broad claims covering variants and therapeutic methods.
- The patent’s uniqueness resides in its epitope focus, antibody engineering claims, and application scope, reinforcing its strategic importance.
- The landscape is highly competitive, with key players including Genentech, Merck, and AstraZeneca, emphasizing patent robustness and innovation.
- Its scope supports current and next-generation immuno-oncology biologics but faces challenges from prior art and patent examination processes.
- Stakeholders must carefully evaluate patent claims for freedom-to-operate and potential licensing opportunities.
References
- U.S. Patent 10,716,799. “Anti-PD-L1 Monoclonal Antibodies and Uses.” Granted July 28, 2020.
- WO Patent Application 2019/104146. International Patent Application related to similar antibody technology.
- FDA approvals and patent landscapes for PD-L1 inhibitors, clinical trial data, and related biosimilars.
- Industry reports on immuno-oncology patent trends from IAM Patent Report (2021).
- Key publications on antibody engineering and PD-L1 epitope mapping.
